First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

被引：65
|
作者：
Siefker-Radtke, Arlene O.
Necchi, Andrea
Park, Se Hoon
GarcAa-Donas, JesAs
Huddart, Robert A.
Burgess, Earle Frederick
Fleming, Mark T.
Rezazadeh, Arash
Mellado, Begona
Varlamov, Sergei
Joshi, Monika
Duran, Ignacio
Tagawa, Scott T.
OHagan, Anne
Avadhani, Anjali Narayan
Zhong, Bob
De Porre, Peter
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Ist Nazl Tumori, Milan, Italy
[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Clara Campal Comprehens Canc Ctr CIOCC, Madrid, Spain
[5] Inst Canc Res, Sutton, Surrey, England
[6] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[7] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA
[8] Norton Healthcare, Louisville, KY USA
[9] Inst Investigac Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain
[10] Altai Reg Canc Ctr, Barnaul, Russia
[11] Penn State Canc Inst, Hershey, PA USA
[12] Hosp Univ Marques Valdecilla, Santander, Spain
[13] Weill Cornell Med Coll, Div Hematol Med Oncol, Dept Urol, Meyer Canc Ctr, New York, NY USA
[14] New York Presbyterian Hosp, New York, NY USA
[15] Janssen Res & Dev, Spring House, PA USA
[16] Janssen Res & Dev, Beerse, Belgium
[17] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
    Loriot, Yohann
    Necchi, Andrea
    Park, Se Hoon
    Garcia-Donas, Jesus
    Huddart, Robert A.
    Burgess, Earle Frederick
    Fleming, Mark T.
    Rezazadeh, Arash
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    OHagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    Stuyckens, Kim
    Dosne, Anne-Gaelle
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    Santiago-Walker, Ademi E.
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations
    Siefker-Radtke, A. O.
    Mellado, B.
    Decaestecker, K.
    Burke, J. M.
    O'Hagan, A.
    Avadhani, A.
    Zhong, B.
    Santiago-Walker, A.
    De Porre, P.
    Brookman-May, S.
    Garcia-Donas, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
    Loriot, Y.
    Matsubara, N.
    Huddart, R. A.
    Houede, N.
    Laguerre, B.
    Guadalupi, V.
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1201 - S1201
  • [5] A phase II study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali
    Zhong, Bob
    Santiago-Walker, Ademi
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    CANCER RESEARCH, 2016, 76
  • [6] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
    Loriot, Yohann
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Houede, Nadine
    Banek, Severine
    Laguerre, Brigitte
    Guadalupi, Valentina
    Ku, Ja Hyeon
    Triantos, Spyros
    Akapame, Sydney
    Deprince, Kris
    Mukhopadhyay, Sutapa
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [7] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
    Banek, S.
    Loriot, Y.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Houede, N.
    Laguerre, B.
    Guadalupi, V
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 94 - 94
  • [8] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Houede, Nadine
    Banek, Severine
    Laguerre, Brigitte
    Guadalupi, Valentina
    Ku, Ja Hyeon
    Triantos, Spyros
    Akapame, Sydney
    Deprince, Kris
    Mukhopadhyay, Sutapa
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4619 - LBA4619
  • [9] Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study
    Siefker-Radtke, Arlene O.
    Powles, Thomas
    Moreno, Victor
    Kang, Taek Won
    Cicin, Irfan
    Girvin, Angela
    Akapame, Sydney
    Triantos, Spyros
    O'Hagan, Anne
    Zhu, Wei
    Tammaro, Meggan
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study
    Imkamp, Florian
    Loriot, Yohann
    Necchi, Andrea
    Park, Se Hoon
    Huddart, Robert
    Burgess, Earle
    Fu, Min
    Santiago-Walker, Ademi
    Mukhopadhyay, Sutapa
    Naini, Vahid
    Deprince, Kris
    Monga, Manish
    Siefker-Radtke, Arlene
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 78 - 78
12345